Effectiveness of HIV Treatment with Stavudine, Lamivudine, and Nevirapine
Author Information
Author(s): Manosuthi Weerawat, Tantanathip Preecha, Prasithisirikul Wisit, Likanonsakul Sirirat, Sungkanuparph Somnuek
Primary Institution: Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand
Hypothesis
Does the co-administration of rifampicin affect the durability of HIV treatment with stavudine, lamivudine, and nevirapine?
Conclusion
The treatment regimen of stavudine, lamivudine, and nevirapine is effective for HIV-1 infected patients, regardless of rifampicin co-administration.
Supporting Evidence
- 59.3% of patients achieved undetectable HIV-1 RNA levels after 144 weeks.
- 61.4% of patients in the TB group achieved undetectable HIV-1 RNA.
- 57.1% of patients in the control group achieved undetectable HIV-1 RNA.
- 5.8% of patients discontinued treatment due to adverse effects.
- The study included a diverse group of patients with varying tuberculosis diagnoses.
Takeaway
This study shows that a combination of three HIV medicines works well for patients, even if they are also being treated for tuberculosis.
Methodology
A prospective cohort study involving 140 HIV-infected patients, with 70 receiving rifampicin for tuberculosis and 70 not receiving it.
Potential Biases
Potential bias due to the study's design and the specific population studied.
Limitations
The sample size may not be sufficient to detect long-term differences in antiviral responses.
Participant Demographics
140 HIV-infected Thai patients, aged 15 and older, with a median baseline CD4 count of 31 cells/mm3.
Statistical Information
P-Value
0.731
Confidence Interval
95%CI = 0.608–2.346
Statistical Significance
p=0.731
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website